Wells Fargo Maintains Hold Rating and $5 Price Target for Zentalis Pharmaceuticals
Wells Fargo analyst Yanan Zhu has maintained a Hold rating and a $5 price target on Zentalis Pharmaceuticals.
Stocks · News reference
Zentalis Pharmaceuticals announced its financial results for the third quarter ended September 30, 2026, reporting a cash position of $228.9 million.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Wells Fargo analyst Yanan Zhu has maintained a Hold rating and a $5 price target on Zentalis Pharmaceuticals.
Wedbush upgraded Zentalis Pharmaceuticals from Neutral to Outperform and increased its price target for the company's stock to $6 from $5.
Filed: 2026-11-09 AccNo: 0001725160-26-000069 Size: 5 MB Item 2.02: Results of Operations and Financial Condition Item 7.01: Regulation FD Disclosure
Zentalis Pharmaceuticals announced that its management team will participate in two investor conferences in November 2026.